Compare Atlassian Corporation PLC (TEAM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs Viatris Inc — how do they compare? Atlassian Corporation PLC trades at $152.51 (market cap $39.10B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Atlassian Corporation PLC is far larger — about 2.1× Viatris Inc's market cap, and Viatris Inc pays a 2.95% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| TEAM | VTRS | |
|---|---|---|
Market Cap | $39.10B | $18.69B |
Sector | Technology | Health |
52-Week High | $182.36 | $17.86 |
52-Week Low | $57.15 | $9.49 |
Enterprise Value | $39.09B | $30.80B |
Dividend Yield | — | 2.95% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
